medigraphic.com

2016, Número 1

<< Anterior Siguiente >>

Rev Mex Anest 2016; 39 (1)


Actualidades conceptuales sobre fibromialgia

Covarrubias-Gómez A, Carrillo-Torres O

Idioma: Español
Referencias bibliográficas: 52
Paginas: 58-63
Archivo PDF: 277.72 Kb.


RESUMEN

La fibromialgia es un padecimiento doloroso frecuentemente reportado. Afecta predominantemente a mujeres en edad reproductiva. Dicho padecimiento en ocasiones limita las actividades cotidianas e impacta las condiciones asociadas con la vida. En nuestros días aún se desconocen diversos aspectos etiogénicos de la enfermedad, no obstante se ha recomendado que su diagnóstico temprano podría beneficiar a la población afectada. Para poder proporcionar estrategias útiles que alivien el dolor de estos enfermos se sugieren esquemas farmacológicos y no-farmacológicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Covarrubias-Gómez A, Guevara-López U, Gutiérrez-Salmerón C, Betancourt-Sandoval JA, Córdova-Domínguez JA. Epidemiología del dolor crónico en México. Rev Mex Anest. 2010;33:207-213.

  2. Covarrubias-Gómez A, Guevara-López U, Lara-Solares A, Tamayo-Valenzuela AC, Salinas-Cruz J, Torres-González R. Características de los enfermos que acuden a una clínica del dolor por primera vez. Rev Med Inst Mex Seguro Soc. 2008;46:467-472.

  3. Gordillo-Álvarez V, Ramírez-Bermejo A, Solís-Valadez GP, Bautista-Sánchez SG, Kassian-Rank A. Causas de dolor crónico en el Hospital General de México. Dolor Clin Ter. 2004;10:15-23.

  4. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromialgia in the general population. Arthritis Rheum. 1995;38:19-28.

  5. Croft PR. The epidemiology of chronic widespread pain. J Musculoskel Pain. 2002;10:191-199.

  6. Gran JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol. 2003;17:547-561.

  7. McCarberg BH. Clinical overview of fibromyalgia. Am J Ther. 2012;19:357-368.

  8. Bartels EM, Dreyer L, Jacobsen S, Jespersen A, Bliddal H, Danneskiold-Samsøe B. Fibromyalgia, diagnosis and prevalence. Are gender differences explainable? Ugeskr Laeger. 2009;171:3588-3592.

  9. [No authors listed]. Management of fibromyalgia. Drug Ther Bull. 2010;48:89-93.

  10. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromialgia. Am J Health Syst Pharm. 201;68:1307-1319.

  11. Clark P. Frecuencias y características de la fibromialgia en el Hospital General de México: revisión de la Epidemiología. Rev Mex Reumatol. 2001;16:191-197.

  12. Cruz-Franco L, Tamayo-Valenzuela AC, Guevara-López U, Bautista-Eugenio V. Tratamiento farmacológico de fibromialgia: experiencia de tres años. Rev Fac Med UNAM. 2010;53:11-18.

  13. Ablin JN, Buskila D, Clauw DJ. Biomarkers in fibromyalgia. Curr Pain Headache Rep. 2009;13:343-349.

  14. Valença MM, Medeiros FL, Martins HA, Massaud RM, Peres MF. Neuroendocrine dysfunction in fibromyalgia and migraine. Curr Pain Headache Rep. 2009;13:358-364.

  15. Rao SG. Current progress in the pharmacological therapy of fibromyalgia. Expert Opin Investig Drugs. 2009;18:1479-1493.

  16. Chong YY, Ng BY. Clinical aspects and management of fibromyalgia syndrome. Ann Acad Med Singapore. 2009;38:967-973.

  17. Schmidt-Wilcke T, Wood P, Lürding R. Cognitive impairment in patients suffering from fibromyalgia. An underestimated problem. Schmerz. 2010;24:46-53.

  18. Iqbal R, Mughal MS, Arshad N, Arshad M. Pathophysiology and antioxidant status of patients with fibromyalgia. Rheumatol Int. 2011;31:149-152.

  19. Di Franco M, Iannuccelli C, Valesini G. Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci. 2010;1193:84-90.

  20. Cordero MD, de Miguel M, Moreno-Fernández AM. Mitochondrial dysfunction in fibromyalgia and its implication in the pathogenesis of disease. Med Clin (Barc). 2011;136:252-256.

  21. Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. Arthritis Res Ther. 2009;11:242.

  22. Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatol Int. 2012;32:417-426.

  23. Mahdi AA, Fatima G, Das SK, Verma NS. Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys. 2011;48:82-87.

  24. Simms RW. Is there muscle pathology in fibromyalgia syndrome? Rheum Dis Clin North Am. 1996;22:245-266.

  25. Bachasson D, Guinot M, Wuyam B, Favre-Juvin A, Millet GY, Levy P, et al. Neuromuscular fatigue and exercise capacity in fibromyalgia syndrome. Arthritis Care Res (Hoboken). 2013;65:432-440.

  26. Gerdle B, Söderberg K, Salvador-Puigvert L, Rosendal L, Larsson B. Increased interstitial concentrations of pyruvate and lactate in the trapezius muscle of patients with fibromyalgia: a microdialysis study. J Rehabil Med. 2010;42:679-687.

  27. Katz DL, Greene L, Ali A, Faridi Z. The pain of fibromyalgia syndrome is due to muscle hypoperfusion induced by regional vasomotor dysregulation. Med Hypotheses. 2007;69:517-525.

  28. McIver KL, Evans C, Kraus RM, Ispas L, Sciotti VM, Hickner RC. No-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain. 2006;120:161-169.

  29. Diaz-Piedra C, Di Stasi LL, Baldwin CM, Buela-Casal G, Catena A. Sleep disturbances of adult women suffering from fibromyalgia: a systematic review of observational studies. Sleep Med Rev. 2015;21:86-99.

  30. Paul-Savoie E, Marchand S, Morin M, Bourgault P, Brissette N, Rattanavong V, et al. Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol J. 2012;6:296-302.

  31. WHO “World Health Organization”. Classification of diseases [Online]. [Fecha de consulta: 30 de mayo de 2015]. Disponible en: http://apps.who.int/classifications/icd10/browse/2010/en

  32. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38:1113-1122.

  33. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Am J Ther. 2010;17:418-439.

  34. Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of phase III clinical trials. Expert Opin Pharmacother. 2010;11:2805-2812.

  35. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain. 2009;145:69-81.

  36. Malemud CJ. Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome. Clin Exp Rheumatol. 2009;27:S86-S91.

  37. Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheum Dis. 2011;14:6-11.

  38. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11:505-521.

  39. Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011;50:532-543.

  40. Roskell NS, Beard SM, Zhao Y, Le TK. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11:516-527.

  41. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome: a systematic review. Eur J Pain. 2010;14:5-10.

  42. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010;12:R79.

  43. Arnold B, Häuser W, Arnold M, Bernateck M, Bernardy K, Brückle W, et al. Multicomponent therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz. 2012;26:287-290.

  44. Bernardy K, Füber N, Köllner V, Häuser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome-a systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2010;37:1991-2005.

  45. Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010;151:280-295.

  46. Langhorst J, Musial F, Klose P, Häuser W. Efficacy of hydrotherapy in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Rheumatology (Oxford). 2009;48:1155-1159.

  47. Fraioli A, Grassi M, Mennuni G, Geraci A, Petraccia L, Fontana M, et al. Clinical researches on the efficacy of spa therapy in fibromyalgia. A systematic review. Ann Ist Super Sanita. 2013;49:219-229.

  48. Ernst E. Chiropractic treatment for fibromyalgia: a systematic review. Clin Rheumatol. 2009;28:1175-1178.

  49. Perry R, Terry R, Ernst E. A systematic review of homoeopathy for the treatment of fibromyalgia. Clin Rheumatol. 2010;29:457-464.

  50. Langhorst J, Klose P, Musial F, Irnich D, Häuser W. Efficacy of acupuncture in fibromyalgia syndrome: a systematic review with a meta-analysis of controlled clinical trials. Rheumatology (Oxford). 2010;49:778-788.

  51. Deare JC, Zheng Z, Xue CC, Liu JP, Shang J, Scott SW, et al. Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev. 2013;5:CD007070.

  52. Cao H, Liu J, Lewith GT. Traditional Chinese medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials. J Altern Complement Med. 2010;16:397-409.




2020     |     www.medigraphic.com